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Dear Editor, 28 
 29 
Bone is an endocrine organ that produces key hormones and cytokines (Green et al., 2015b). 30 
Paget’s Disease of Bone (PDB) is a polygenic disorder of bone turnover first described by Sir 31 
James Paget in 1876. PDB is characterised by hyper differentiation and hyper activity of 32 
osteoclast cells which induces increased bone remodelling by osteoblasts. The resultant 33 
mosaic of bone is structurally weaker, larger, more vascular and porous with an increased 34 
susceptibility to fracture. On histology the osteoclasts are increased in size, population and 35 
number of nuclei, expressing a “pagetic phenotype” that distinguishes them from normal 36 
osteoclasts. Malignant transformation is a rare complication of PDB reported to arise in <1% 37 
of PDB patients. Paget’s associated osteosarcoma (PDB-OS) consistently arises in sites of 38 
pagetic bone and may present with multifocal lesions (Hansen et al., 2006). On histology the 39 
lesions are osteoblastic and characterised as an exaggerated form of the accelerated bone 40 
remodelling that manifests in PDB. Median survival at diagnosis is 21 months for those treated 41 
with curative intent and 7 months for those treated palliatively (Shaylor et al., 1999).  42 
 43 
PDB has a strong genetic component. A number of loci have been linked to the disorder with 44 
sequestosome 1 (SQSTM1) variants associated with more severe symptoms, polyostotic foci 45 
and heritable transmission (Hansen et al., 2006). SQSTM1 is multifunctional protein which 46 
serves as a signalling hub for diverse cellular events including activation of nuclear factor 47 
kappa B (NFKB) and tumour necrosis factor superfamily member 11 (TNFSF11). SQSTM1 48 
also serves as an autophagy receptor for degradation of ubiquitinated molecules via its 49 
ubiquitin binding domain (Katsuragi et al., 2015). SQSTM1 variants associated with PDB are 50 
typically located within the coding region of the ubiquitin binding domain. Impairment of 51 
autophagy is accompanied by massive accumulation of SQSTM1 and formation of SQSTM1-52 
positive aggregate structures (Katsuragi et al., 2015). As the role of SQSTM1 has not been 53 
fully elucidated in transformation and there is no transcriptomic analysis of this cancer, we 54 
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took a next generation sequencing approach to evaluate the expression of small RNAs such 55 
as microRNAs (miRNAs) in PDB and PDB-OS.  56 
 57 
MiRNAs are key regulators of gene expression through gene silencing. MiRNAs can also be 58 
used as biomarkers to classify poorly differentiated cancers and cancer tissue origin (Green 59 
et al., 2015a). We extracted RNA using the miRCURY RNA isolation kit (Exiqon) from two 60 
tissue specimens of PDB-OS with a proven histological diagnosis of osteosarcoma in Paget’s 61 
affected bone (ages 73 and 81, 2 men). We extracted RNA from four SQSTM1-positive PDB 62 
tissue specimens taken from affected trabecular bone (ages 79-87, 2 women and 2 men). We 63 
extracted RNA from five control bone tissue specimens taken from the femoral heads of 64 
trauma patients (ages 68-86, 3 women and 2 men). Tissue samples were collected and 65 
preserved at -20 oC. RNA was stored at -80 oC. We generated small RNA libraries using high 66 
definition (HD) adapters as previously described (Xu et al., 2015). HD adapters increase the 67 
annealing efficiency between small RNAs and adapters. An increased annealing efficiency 68 
significantly reduces the RNA ligase-dependent ligation bias in next generation sequencing 69 
studies (Xu et al., 2015). We performed sequencing on the HiSeq 2500 Ultra-High-Throughput 70 
Sequencing System (Illumina) at the Earlham Institute, Norwich Research Park.  71 
 72 
Raw fastq files were converted to fasta format. The HD signatures of the sequencing reads 73 
were trimmed. Quality checking was performed using The UEA Small RNA Workbench 74 
(www.srna-workbench.cmp.uea.ac.uk). Reads were mapped with no gaps allowed to the 75 
human genome v38 using PatMaN. Small RNA expression levels were normalised using a 76 
scaling approach, reads per total, to a fixed total of 10 million reads (Mohorianu et al., 2011). 77 
Comparison  of  the  samples  was  conducted  using  scatter plots,  size-split  boxplot  of the 78 
replicate-to-replicate differential  expression,  intersection  and Jaccard  similarity  analyses 79 
(Mohorianu et al., 2011). Differentially expressed reads between the control, PDB and PDB-80 
OS samples were identified using both an expression interval approach and pairwise 81 
comparison using offset fold change (Mohorianu et al., 2011; Mohorianu et al., 2013). Analysis 82 
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was conducted using custom made Perl (5.24.0.1) and R (3.2.2) scripts. We observed a high 83 
proportion of reads matching to the reference genome (Table 1). The size class distributions 84 
were bimodal with peaks at 22 and 32 nt (Figure 1). These peaks correspond to miRNAs and 85 
tRNA fragments which was confirmed using annotations. The small number of unique 86 
sequences with high abundance is also visible in the complexity distributions (Figure 1). The 87 
lower complexities correspond to 22 and 32 nt which indicate a small number of highly 88 
abundant sequences (Figure 1). As with all human studies there was variability in the number 89 
of reads assigned to either miRNAs or tRNA fragments in the control samples (when 90 
compared to inbred genetic models such as mice and fruit flies where variability is minimal). 91 
We identified a low expression of miR-16 in PDB compared to controls and a high expression 92 
of miR-16 in PDB-OS compared to controls and PDB. We also identified a downregulation of 93 
miR-144 and upregulation of miR-21 in PDB-OS compared to controls. Downregulation of 94 
miR-144 is in line with previous data in osteosarcoma cells. Upregulation of miR-21 is 95 
associated with many types of cancer. In this study we explored miR-16 further.   96 
 97 
Total RNA used for next generation sequencing was quantified by density measurement after 98 
separation by agarose gel electrophoresis with ethidium bromide staining. Equal amounts of 99 
RNA across the sample pools were reverse transcribed using the TaqMan advanced miRNA 100 
cDNA synthesis kit (Thermo Fisher Scientific). Differential expression of miR-16 was validated 101 
three times in triplicate using TaqMan miRNA advanced assays (Thermo Fisher Scientific). 102 
Digital PCR was performed on the QuantStudio 3D Digital PCR System using the GeneAmp 103 
PCR System 9700 (Thermo Fisher Scientific). After PCR the chips were imaged on the 104 
QuantStudio 3D Instrument which assesses raw data and calculates the concentration of the 105 
cDNA sequence targeted by FAM and VIC labelled probes by Poisson distribution (Fazekas 106 
de St, 1982). For more in depth analysis the QuantStudio 3D AnalysisSuite was used to report 107 
the data as copies/µL. Probe sequence used was miR-16-5p (5’-108 
UAGCAGCACGUAAAUAUUGGCG-3’). We confirmed the downregulation of miR-16 in PDB 109 
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compared to controls and upregulation of miR-16 in PDB-OS compared to controls and PDB 110 
(Figure 1).  111 
 112 
To elucidate a mechanistic role of miR-16 in PDB-OS we used TargetScan v7.1 to search for 113 
its messenger RNA targets. SQSTM1 was identified as a candidate which was supported by 114 
performing a second search and identification on miRSearch v3. Target identification of 115 
miRNAs is computationally difficult due to the relatively low homology between miRNAs and 116 
their targets. We searched the literature and identified SQSTM1 as an experimentally 117 
confirmed target of miR-16, i.e. levels of SQSTM1 are reduced by miR-16 overexpression 118 
(Selbach et al., 2008). We find that miR-16 is downregulated in PDB which means there is a 119 
loss of SQSTM1 negative regulation. In line with previous data SQSTM1 variants in PDB are 120 
activating mutations. SQSTM1 is a signalling hub for the activation of TNFSF11. TNFSF11 is 121 
the primary ligand for stimulating the differentiation of monocyte progenitors to osteoclasts 122 
through interaction with tumour necrosis factor receptor superfamily member 11a 123 
(TNFRSF11A). TNFSF11 is produced by osteoblasts and downstream repercussions of the 124 
TNFSF11-TNFRSF11 interaction is the increase of bone resorption. Bone resorption achieved 125 
by various osteoclast-produced cytokines is set within a positive feedback loop which 126 
encourages osteoblast proliferation and activity. Increased proliferation of osteoblast cells 127 
containing SQSTM1 activating variants repeats the bone remodelling cycle each time 128 
increasing the number of SQSTM1 positive osteoblasts. PDB does not typically present until 129 
patients are >55-years-old. In patients harbouring SQSTM1 variants, presentation can appear 130 
earlier. Presentation may be due to the speed of the bone remodelling cycle or the gradual 131 
loss of miR-16 mediated silencing of SQSTM1.  132 
 133 
We find a high expression of miR-16 in PDB-OS. The effect of upregulated miR-16 means 134 
there is increased negative regulation of genes including SQSTM1. Loss of SQSTM1 has little 135 
effect on autophagy (Katsuragi et al., 2015). The lack of phenotypic impact might be explained 136 
by the presence of other autophagy regulators including optineurin (OPTN) (Katsuragi et al., 137 
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2015). As a signalling hub SQSTM1 is a partner of the Kelch like ECH associated protein 1 138 
(KEAP1)-nuclear factor erythroid 2 like 2 (NFE2L2) pathway, a major cellular defence 139 
mechanism against oxidative stress (Katsuragi et al., 2015). In normal conditions NFE2L2 is 140 
constitutively degraded by the ubiquitin-proteasome system because its binding partner 141 
KEAP1 is an adapter of ubiquitin ligases. Upon exposure to oxidative stress KEAP1 is 142 
structurally modified which releases NFE2L2 to translocate to the nucleus. NFE2L2 is a 143 
transcription factor which then induces a multitude of antioxidant and anti-inflammatory genes. 144 
SQSTM1 is able to abrogate the interaction between KEAP1 and NFE2L2 leading to protection 145 
against oxidative stress (Katsuragi et al., 2015). We propose miR-16 mediated silencing of 146 
SQSTM1 incapacitates the cell’s ability to protect itself against oxidative stress-induced 147 
oncogenesis. This proposal warrants further molecular investigation to show an inverse 148 
correlation between the expression of miR-16 and SQSTM1.  149 
 150 
Molecular testing may help provide a robust diagnosis and is particularly useful in rare 151 
cancers. This is especially true in PDB where transformation to osteosarcoma is often missed 152 
until late stage. Radiograph morphology is subtly different between PDB and PDB-OS. 153 
Symptoms of PDB-OS can be similar to the day-to-day symptoms experienced by a PDB 154 
patient. Biomarkers such as serum total alkaline phosphatase used in the diagnosis of PDB 155 
are the same biomarkers used to aid the diagnosis of PDB-OS. These features combined 156 
make it difficult to distinguish between a chronic non-life threatening disorder and a fatal 157 
disease which require very different treatment strategies. Quantitative PCR or next generation 158 
sequencing performed on RNA extracted from a biopsy of a presenting lesion is precise for 159 
detecting a reduced expression of miR-16 in ‘normal PDB’ and high expression of miR-16 in 160 
PDB-OS. The switch in miR-16 expression could alert physicians to the change to an 161 
osteosarcoma phenotype.  162 
 163 
A limitation of this study is the size of the cohorts studied. PDB-OS arises in <1% of PDB 164 
patients and donation to tissue banks is scarce. We are in the process of collecting a larger 165 
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cohort of tissue specimens to validate the findings from this study. Our data highlights the 166 
value of being able to provide a robust tissue diagnosis in addition to identifying regulatory 167 
transcriptomic molecules that could be exploited for targeted therapy. Expression of miR-16 168 
could also be investigated in paediatric osteosarcoma to evaluate similarities and/or 169 
differences between the two age-related incidence peaks of osteosarcoma.  170 
 171 
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